Merck Receives FDA Approval for Keytruda in Endometrial Carcinoma

Merck today announced that the FDA has approved KEYTRUDA (pembrolizumab) in combination with lenvatinib for adults with advanced endometrial carcinoma that is not microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR), who have disease progression following prior systemic therapy. In the Phase 3 KEYNOTE-775/Study 309 trial, the combination demonstrated a statistically significant improvement in overall survival and progression-free survival compared to chemotherapy. The median OS was 18.3 months for the combination versus 11.4 months for chemotherapy. This approval provides a new treatment option for patients with this difficult-to-treat cancer.